Analysts Set Expectations for PVLA Q2 Earnings

Key Points

• Analysts at Lifesci Capital have issued forecasts for Palvella Therapeutics, predicting Q2 2025 earnings per share (EPS) of ($0.77), with a full-year estimate of ($3.69) EPS for 2025.
• Palvella Therapeutics has an average analyst rating of "Buy" with a consensus target price of $52.40.
• Recently, large institutional investors have increased their stake in Palvella Therapeutics, now holding 40.11% of the company's stock.

Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) - Research analysts at Lifesci Capital issued their Q2 2025 earnings per share (EPS) estimates for shares of Palvella Therapeutics in a research note issued to investors on Monday, August 4th. Lifesci Capital analyst S. Slutsky expects that the company will post earnings of ($0.77) per share for the quarter. Lifesci Capital has a "Outperform" rating and a $90.00 price target on the stock. The consensus estimate for Palvella Therapeutics' current full-year earnings is ($3.69) per share. Lifesci Capital also issued estimates for Palvella Therapeutics' Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.81) EPS, FY2025 earnings at ($3.13) EPS and FY2026 earnings at ($3.64) EPS.

Several other equities analysts have also issued reports on the company. Raymond James Financial assumed coverage on Palvella Therapeutics in a report on Tuesday. They issued an "outperform" rating and a $54.00 target price for the company. Truist Financial assumed coverage on Palvella Therapeutics in a research note on Monday, July 21st. They issued a "buy" rating and a $56.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and issued a $38.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, April 30th. Finally, Canaccord Genuity Group dropped their price objective on Palvella Therapeutics from $53.00 to $52.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. Nine analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $52.40.

Palvella Therapeutics Trading Up 4.7%

Shares of PVLA stock traded up $1.85 during trading on Wednesday, hitting $40.90. The company's stock had a trading volume of 106,508 shares, compared to its average volume of 187,830. The company has a market cap of $452.35 million, a PE ratio of -3.38 and a beta of -0.01. The business has a fifty day moving average of $28.49 and a 200-day moving average of $24.31. Palvella Therapeutics has a 52 week low of $11.17 and a 52 week high of $41.00.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.40) by $2.66.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PVLA. Geode Capital Management LLC bought a new position in shares of Palvella Therapeutics during the fourth quarter valued at about $171,000. Renaissance Technologies LLC purchased a new stake in shares of Palvella Therapeutics during the fourth quarter worth about $256,000. Blue Owl Capital Holdings LP purchased a new stake in shares of Palvella Therapeutics during the fourth quarter worth about $3,001,000. Nantahala Capital Management LLC purchased a new stake in shares of Palvella Therapeutics during the fourth quarter worth about $3,001,000. Finally, Samsara BioCapital LLC purchased a new stake in shares of Palvella Therapeutics during the fourth quarter worth about $8,154,000. 40.11% of the stock is owned by institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.